KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EBITDA (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed EBITDA for 8 consecutive years, with $61.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 390.04% year-over-year to $61.8 million, compared with a TTM value of -$22.7 million through Dec 2025, up 56.17%, and an annual FY2025 reading of -$22.7 million, up 56.17% over the prior year.
  • EBITDA was $61.8 million for Q4 2025 at Esperion Therapeutics, up from -$31.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $61.8 million in Q4 2025 and bottomed at -$90.9 million in Q1 2021.
  • Average EBITDA over 5 years is -$39.3 million, with a median of -$52.4 million recorded in 2022.
  • Peak annual rise in EBITDA hit 390.04% in 2025, while the deepest fall reached 166.3% in 2025.
  • Year by year, EBITDA stood at -$65.1 million in 2021, then rose by 14.97% to -$55.4 million in 2022, then decreased by 1.71% to -$56.3 million in 2023, then skyrocketed by 62.16% to -$21.3 million in 2024, then skyrocketed by 390.04% to $61.8 million in 2025.
  • Business Quant data shows EBITDA for ESPR at $61.8 million in Q4 2025, -$31.3 million in Q3 2025, and -$12.7 million in Q2 2025.